Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $27.48, for a total value of $412,200.00. Following the sale, the insider owned 460,215 shares in the company, valued at $12,646,708.20. The trade was a 3.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Brian Daniel Webster also recently made the following trade(s):

• On Tuesday, August 4th, Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.52, for a total value of $1,272,588.00.
• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.92, for a total value of $311,366.64.
• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total value of $202,224.80.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.72, for a total transaction of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00.

Kestra Medical Technologies Stock Up 0.4%

KMTS stock opened at $27.93 on Wednesday. The stock has a market cap of $1.64 billion, a PE ratio of -11.54 and a beta of 0.58. The firm’s 50-day simple moving average is $24.13 and its 200 day simple moving average is $22.74. Kestra Medical Technologies, Ltd. has a fifty-two week low of $15.42 and a fifty-two week high of $30.00. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. As a group, sell-side analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KMTS. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. BTIG Research increased their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Kestra Medical Technologies presently has a consensus rating of “Hold” and a consensus target price of $28.14.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in Kestra Medical Technologies during the 1st quarter valued at $11,036,000. Woodline Partners LP bought a new stake in shares of Kestra Medical Technologies in the 1st quarter worth $2,510,000. Jane Street Group LLC bought a new stake in shares of Kestra Medical Technologies in the 1st quarter worth $756,000. Geode Capital Management LLC lifted its holdings in shares of Kestra Medical Technologies by 718.5% in the second quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after buying an additional 285,579 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in Kestra Medical Technologies during the second quarter valued at about $256,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.